{"organizations": [], "uuid": "f96df51b45ac095f334f7627ec30d729591950f6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-celldexs-metric-study-in-metastati/brief-celldexs-metric-study-in-metastatic-triple-negative-breast-cancer-does-not-meet-primary-endpoint-idUSFWN1RT09Z", "country": "US", "domain_rank": 408, "title": "BRIEF-Celldex’S Metric Study In Metastatic Triple-Negative Breast Cancer Does Not Meet Primary Endpoint", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-16T14:05:00.000+03:00", "replies_count": 0, "uuid": "f96df51b45ac095f334f7627ec30d729591950f6"}, "author": "", "url": "https://www.reuters.com/article/brief-celldexs-metric-study-in-metastati/brief-celldexs-metric-study-in-metastatic-triple-negative-breast-cancer-does-not-meet-primary-endpoint-idUSFWN1RT09Z", "ord_in_thread": 0, "title": "BRIEF-Celldex’S Metric Study In Metastatic Triple-Negative Breast Cancer Does Not Meet Primary Endpoint", "locations": [], "entities": {"persons": [], "locations": [{"name": "xeloda", "sentiment": "none"}], "organizations": [{"name": "brief-celldex’s metric", "sentiment": "neutral"}, {"name": "celldex therapeutics inc", "sentiment": "none"}, {"name": "meet primary endpoint reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 16 (Reuters) - Celldex Therapeutics Inc:\n* CELLDEX’S METRIC STUDY IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER DOES NOT MEET PRIMARY ENDPOINT\n* CELLDEX THERAPEUTICS INC - GLEMBATUMUMAB VEDOTIN SAFETY PROFILE WAS CONSISTENT WITH PRIOR EXPERIENCE\n* CELLDEX THERAPEUTICS INC - EVALUATING OUR OPERATIONAL AND WORKFORCE NEEDS TO EXTEND OUR FINANCIAL RESOURCES\n* CELLDEX THERAPEUTICS INC - RANDOMIZED, PHASE 2B METRIC STUDY OF GLEMBATUMUMAB VEDOTIN COMPARED TO XELODA FAILED TO MEET ITS PRIMARY ENDPOINT\n* CELLDEX THERAPEUTICS INC - NO SIGNIFICANT ADVANTAGE FOR GLEMBATUMUMAB VEDOTIN IN KEY SECONDARY ENDPOINTS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": [], "published": "2018-04-16T14:05:00.000+03:00", "crawled": "2018-04-16T14:20:50.030+03:00", "highlightTitle": ""}